Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Cost per responder"'
Autor:
Doris K. Hansen, Xiaoxiao Lu, Omar Castaneda Puglianini, Sonja Sorensen, Saad Z. Usmani, Eileen Zhang, Stephen Huo, Yan Zhang, Zaina P. Qureshi, Sundar Jagannath
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionCiltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell therapy approved for patients with relapsed/refractory multiple myeloma (RRMM). In the phase 3 trial, CARTITUDE-4 (NCT04181827), cilta-cel demonstrated improved e
Externí odkaz:
https://doaj.org/article/faef266a18e64f2baab90aadac26c543
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 25, Iss 1 (2024)
OBJECTIVE: To evaluate the costs and benefits associated with the use of biologics and Janus kinase inhibitors (JAKi) for the treatment of bio-experienced patients suffering from ulcerative colitis in Italy. METHODS: This pharmacoeconomic analysis c
Externí odkaz:
https://doaj.org/article/3c3ee42f6305451c9dab26f5ae31d35f
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 15, Pp 607-619 (2023)
Nanna Nyholm,1 Anne Danø,2 Henrik Schnack,2 Giorgio Lorenzo Colombo3 1LEO Pharma AS, Ballerup, Denmark; 2EY, Frederiksberg, Denmark; 3CEFAT Center of Pharmaceuticals Economics and Medical Technologies Evaluation, Department of Drug Sciences, Univers
Externí odkaz:
https://doaj.org/article/3596c364e3134e6e9147b556d429c7d7
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Pharmacoeconomic studies examining the cost-effectiveness of adalimumab biosimilars versus methotrexate in real-life settings are limited. Objectives To assess the cost per responder from the perspective of the National Health System of ad
Externí odkaz:
https://doaj.org/article/1a30bb46a44849e1839c9941902c4414
Autor:
Emanuela Zagni, Micol Frassi, Giuseppa Pagano Mariano, Enrico Fusaro, Claudia Lomater, Patrizia Del Medico, Florenzo Iannone, Rosario Foti, Massimiliano Limonta, Antonio Marchesoni, Bernd Raffeiner, Ombretta Viapiana, Walter Grassi, Rosa Daniela Grembiale, Giuliana Guggino, Antonino Mazzone, Enrico Tirri, Roberto Perricone, Pier Carlo Sarzi Puttini, Salvatore De Vita, Fabrizio Conti, Alessandro Zullo, Lucia Simoni, Martina Fiocchi, Roberto Orsenigo, Delia Colombo
Publikováno v:
BMC Health Services Research, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background Psoriatic arthritis (PsA) is a chronic, immune-mediated, spondyloarthropathy characterised by musculoskeletal signs and symptoms with associated joint pain and tenderness. The average worldwide PsA prevalence is 133/100,000, while
Externí odkaz:
https://doaj.org/article/d33db92d7da54d9293278239e423073c
Publikováno v:
AboutOpen, Vol 10, Iss 1 (2023)
Background: The aim of this economic evaluation was to compare the cost per responder between vedolizumab and ustekinumab in patients with Crohn’s disease (CD) after failure of tumor necrosis factor-α inhibitors in Italy. Methods: Clinical effica
Externí odkaz:
https://doaj.org/article/00f6771f147c4d7783b41dd30ef415f4
Autor:
Giuseppe Pompilio, Davide Integlia
Publikováno v:
Global & Regional Health Technology Assessment, Vol 9, Iss 1 (2022)
Objective: Conventional synthetic disease modifying antirheumatic drugs (csDMARDs) were recommended in 2019 as first line therapy from Italian Medicines Agency (AIFA) for the treatment of moderate to severe psoriasis. Updated local guidelines recomme
Externí odkaz:
https://doaj.org/article/59bfc528f9a14858b9c78a8baec64bb8
Publikováno v:
Rheumatology and Therapy, Vol 7, Iss 1, Pp 165-171 (2020)
Abstract Introduction The cost-effectiveness of different biologic therapies can be an important component in guiding treatment decisions for patients with rheumatoid arthritis (RA). The objective of this study was to compare drug and adverse event c
Externí odkaz:
https://doaj.org/article/875293ce90c748b491762d3bcac0e7b7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Global & Regional Health Technology Assessment, Vol 8 (2021)
Purpose: The objective of this analysis was to compare the cost per responder between risankizumab and secukinumab among patients with moderate-to-severe plaque psoriasis in Italy. Methods: The clinical efficacy was assessed based on IMMerge study o
Externí odkaz:
https://doaj.org/article/9e9a26d25b4c42ad8f130217f51c05bd